We have demonstrated the potential of random peptide libraries displayed on adeno-associated virus (AAV)2 to select for AAV2 vectors with improved efficiency for cell type-directed gene transfer. AAV9, however, may have advantages over AAV2 because of a lower prevalence of neutralizing antibodies in humans and more efficient gene transfer in vivo. Here we provide evidence that random peptide libraries can be displayed on AAV9 and can be utilized to select for AAV9 capsids redirected to the cell type of interest. We generated an AAV9 peptide display library, which ensures that the displayed peptides correspond to the packaged genomes and performed four consecutive selection rounds on human coronary artery endothelial cells in vitro. This screening yielded AAV9 library capsids with distinct peptide motifs enabling up to 40-fold improved transduction efficiencies compared with wild-type (wt) AAV9 vectors. Incorporating sequences selected from AAV9 libraries into AAV2 capsids could not increase transduction as efficiently as in the AAV9 context. To analyze the potential on endothelial cells in the intact natural vascular context, human umbilical veins were incubated with the selected AAV in situ and endothelial cells were isolated. Fluorescence-activated cell sorting analysis revealed a 200-fold improved transduction efficiency compared with wt AAV9 vectors. Furthermore, AAV9 vectors with targeting sequences selected from AAV9 libraries revealed an increased transduction efficiency in the presence of human intravenous immunoglobulins, suggesting a reduced immunogenicity. We conclude that our novel AAV9 peptide library is functional and can be used to select for vectors for future preclinical and clinical gene transfer applications.
INTRODUCTION
Endothelial cells have a central role in vascular diseases such as hypertension and atherosclerosis, as well as allograft vasculopathy and stenosis after balloon dilatation or bypass vein grafting. Gene transfer approaches into the endothelium with adenoviral vectors were able to prevent hypertension in spontaneously hypertensive rats. 1, 2 Although adenoviral vectors revealed only a transient expression and strong inflammatory response after endothelial gene transfer in a rabbit model, adeno-associated virus (AAV) vectors enabled a more sustained transduction of endothelial cells. 3 However, transduction efficiency of endothelial cells was found to be very low in vivo 3, 4 and in vitro. 3, 5, 6 Transduction efficiency of endothelial cells could be increased by introduction of an endothelial-targeting peptide identified by phage display within the AAV capsids or selection of random AAV display peptide libraries on endothelial cells. 7--13 Such retargeted vectors resulted in an increase in transduction rates by about 40-fold. Selected peptides allowed transduction of endothelium to a certain extent in vivo.
7--9,11--13 However, these previous approaches used AAV2 serotype vectors that might not be ideal for future clinical approaches because there is a high prevalence of immunoglobulin G against AAV2 in human serum. 14, 15 In contrast, AAV9 serotype vectors are less affected by neutralizing factors in human serum peptide 14 and allow a highly efficient gene transfer after intravenous vector administration. 16--19 Thus, we reasoned that AAV9 vectors might be a more suitable basis for developing an endothelial gene transfer vector using endothelial-targeting peptides. Because peptides identified by phage display might result in conformational changes of the peptide when incorporated directly into the viral surface or might not function efficiently for vector-targeting purposes, combinatorial approaches displaying a library of randomized peptides on the AAV surface 8, 20, 21 or capsid modification by shuffled or error-prone PCR 22--26 may represent an alternative. Therefore, the aims of our study were (i) to identify a suitable insertion site for targeting peptides within the AAV9 capsid surface, (ii) to generate a random AAV9 peptide display library for selection of an AAV9-based targeting vector on endothelial cells and (iii) to compare vectors selected from AAV9 libraries with those from our previous AAV2 libraries. We could confirm that site A589 in the AAV9 capsid is a suitable region for insertion of a targeting peptide as predicted from a structure comparison of AAV9 to AAV2. We were able to successfully insert a highly diverse oligopeptide library into this region and finally selected vectors with reduced immunogenicity enabling highly efficient transduction of endothelial cells in vitro as well as in human umbilical veins in situ.
RESULTS
Endothelium-targeted heptapeptides displayed at AAV9 capsid amino-acid residue A589 modulate the transduction efficiency of AAV9 vectors on human endothelial cells Previously, we have shown that selection of a random AAV2 peptide library displayed in close vicinity to arginine residue R588 involved in heparan sulfate proteoglycan (HSPG) binding, yielded peptides with an improved transduction efficiency of AAV2 vectors for human endothelial cells. 8 Unavailable data of the capsid structure and yet unrevealed binding sites for receptors involved in the transduction process, however, limited the possibilities by which plausible peptide insertion sites could be predicted for AAV9. An alignment of AAV2 and AAV9 capsid sequences revealed a high variability in the amino acid composition surrounding R588 (not shown), suggesting that this region could also be involved in AAV9 tropism. Because of an additional amino acid within the AAV9 capsid sequence the corresponding site to R588 is A589 (Figure 1a , green letters). We engineered a plasmid construct comparable to our previous AAV2 plasmid library by introducing two incompatible SfiI restriction sites in the AAV9-cap open reading frame, which enables cloning of oligonucleotides in an oriented fashion. A frameshift in the capsid open reading frame prevents capsid formation from plasmids without oligonucleotide insertion. The architecture of our construct leads to the production of capsid mutants displaying a heptapeptide at capsid site A589 (VP1 numbering) with modification of the wildtype (wt) sequence at only four residues (Figure 1a , red letters).
We created wt and mutant AAV9 vectors displaying NDVRAVS, an endothelium-targeting peptide obtained by in vitro-selection of an AAV2 library 8 and compared their transduction efficiency to wtAAV2 and AAV2-NDVRAVS on human coronary artery endothelial cells (HCAECs). Although wtAAV2 and wtAAV9 showed transduction efficiencies of 19.2 ± 10.7% and 12.4 ± 3.9%, respectively, AAV2-and AAV9-NDVRAVS improved efficiencies to 71.7±15.7% and 74.2±8.9% transduced cells, respectively (Figure 1b ), confirming our assumption that capsid site A589 has a role in the transduction process of AAV9 vectors and is suitable for insertion of targeting peptides.
The AAV9 peptide library displays random heptameres with a virtually unbiased amino acid distribution After identification of a suitable AAV9 capsid site for the insertion of targeting ligands, we set out to generate a capsid library with random insertions. Oligonucleotides encoding randomized heptapeptides were produced following a NNK-triplet design (N, A, C, G or T; K, G or T) that circumvents the expression of ocher and opal stop codons, but does not restrict the variety of amino acids within the peptide. The random library was cloned and produced at the plasmid level and virus particle level. Both, plasmid and virus library were characterized in terms of complexity and amino acid composition. Counting bacterial colonies after transformation with the plasmid library yielded a complexity of 6.02 Â 10 8 clones for the entire library. Sequence analysis of 79 randomly assigned plasmid clones revealed an amino acid distribution comparable to the theoretical expectation (Supplementary Figure S1a) . The functional complexity of the plasmid library was calculated 3.9 Â 10 8 because 30 out of 79 analyzed clones possessed one or two stop codons within the randomized heptamer.
We used the plasmid library to create the intermediate-step transfer shuttle library that resulted in a total of 3.2 Â 10 12 genome copies (g.c.) and 5 Â 10 7 infectious units (IU), covering the complexity of the plasmid library (Supplementary Table S1a ). Human embryonic kidney cells (HEK)293T were infected with a multiplicity of infection (MOI) of 0.5 IU/cell using the entire transfer shuttle library production, thus functionally maintaining the complexity of the plasmid library in the final virus library. The genomic titer of the final virus library was 4.7 Â 10 11 g.c. in total, and sequence analysis of 70 random clones from the virus library revealed a decreased average presence of cysteines (C), aspartic (D) and glutamic acid (E) and threonine (T) within the heptamere, whereas the presence of asparagine (N) and serine (S) was slightly increased (Supplementary Figure S1a) . Altogether, the analysis of the AAV9 plasmid and virus library suggests a display of random peptides with sufficient diversity and broad amino acid usage for the selection process. Furthermore, these data show that insertion of peptides at capsid site A589 does not hamper genome packaging or capsid assembly.
Selection of the AAV9 library on HCAECs results in enrichment of distinct peptides We applied three different MOIs of 10, 100 or 1000 g.c./cell and selected the AAV9 library four consecutive times on HCAECs. After GGC  GCT  GCA  CAA  AGA  AAC   AAV9 wild-type sequence   GCC  CAG  GCG  CAG  GCA  CAA   G586  N587  R588  Q589  A590  A591   A587  Q588  A589  Q590  A591  Q592   AAV9 modified sequence   GGC  GCC  GCG  CAG  GCA  CAA   G587  Q588  A589  Q  A  A   GGC   G590   GCC   A   CAAG round three and four we analyzed the heptamere composition of several clones recovered from each applied MOI. Independent of selection round or MOI, peptide RGDLRVS represented the most prominent peptide (Figure 2a) . Second most common peptides were NFTRLSA and SLRSPPS with a more restricted distribution than RGDLRVS. Notably, some peptides shared certain residues or had similar sequences (RGD LRVS / FRVG , S / T L / I RSPPS) whereas others differed in amino acid composition (DAKWDYR, GAIPDLR). These results show that three to four rounds of selection of the AAV9 library on HCAECs yielded a consistent enrichment of certain peptides independent of the MOI applied.
Enriched peptides improve transduction efficiency of AAV9 vectors in a serotype-dependent manner, but do not confer specificity for HCAECs To assess the potential of enriched peptides to transduce HCAECs, an enhanced green fluorescent protein (EGFP) reporter gene under control of the cytomegalovirus (CMV) promoter was packaged in AAV9 capsids displaying selected heptapeptides (Figure 2b ). The vector production yielded AAV9 mutant vector titers below those of wtAAV9 or wtAAV2 vectors but generally higher than those of comparable mutant AAV2 vectors (Supplementary Table S1 ). Transduction efficiencies were compared with those of wtAAV9, AAV9-NDVRAVS, as well as to AAV9-TEWDQPF, which displays a random control peptide. Almost all mutant AAV9 vectors displaying any of the selected peptides significantly outperformed wtAAV9, TEWDQPF and endothelium-targeting NDVRAVS at MOIs 1 Â 10 3 (Po0.05) and 1 Â 10 4 (Po0.001) g.c./cell, except NFTRLSA and NNVRGFV, which showed no significant differences to NDVRAVS at MOI 1 Â 10 3 g.c./cell (Figure 2b ). Peptides S L / I RSPPS and NLHSPPA enabled by trend the highest transduction efficiencies at MOI 1 Â 10 4 g.c./cell compared with the other selected peptides.
The improvement of AAV9 transduction by display of endothelium-targeted peptides raised the question whether also specificity is increased. We therefore compared transduction efficiencies of wt and mutant AAV9 vectors displaying SLRSPPS and RGDLRVS on different cell types. At a MOI of 2. Both NDVRAVS and SLRSPPS are peptides that are endotheliumtargeted (HCAECs) but were selected from peptide libraries displayed on different serotype capsids. Although selected originally from an AAV2 random peptide library, NDVRAVS efficiently enhances transduction of AAV9 to 58.4 ± 5.1% in contrast to 2.3±1.6% with wtAAV9 ( Figure 2b ). We therefore wanted to know whether peptide sequences enhance transduction efficiency in a serotype-independent manner and incubated HCAECs at a MOI of 5 Â 10 3 g.c./cell with either wt or mutant AAV2 or AAV9 displaying peptides selected on HCAECs in context of an AAV9 library (SLRSPPS, RGDLRVS, NLHSPPA) or in context of an AAV2 library (NDVRAVS, NSSRDLG, NSVSSAS). Both AAV2 and AAV9 wild-type vectors showed only basal transduction efficiencies of below 10% (Figure 3b ). Overall, analyzed AAV9 peptides displayed on AAV9 capsids yielded the highest transduction efficiencies of HCAECs when compared with AAV2 peptides displayed on AAV2 capsids. Cross-display of AAV9 peptides on AAV2 capsids strongly reduced transduction. Similarly, except for peptide NDVRAVS, efficiency of peptides selected from AAV2 libraries was low when displayed on AAV9 vectors indicating that the peptides are not solely responsible for the modulation of transduction efficiency but highly depend on the capsid context of the serotype they are displayed on.
So far, we could show that our selected peptides improve transduction efficiency over wt and mutant AAV9-NDVRAVS vectors in a serotype-dependent manner, but do not confer endothelium specificity to AAV9. MOI Figure S1b) . We compared transduction efficiencies of fluorescent vectors displaying SLRSPPS or RGDLRVS with co-incubations of non-fluorescent vectors displaying SLRSPPS, RGDLRVS as well as their scrambled counterparts PSLPSRS and SDLRRGV at 75 Â g.c. excess and found significant reductions of transduction in both groups (Figure 4a ). Co-incubation of fluorescent/non-fluorescent SLRSPPS vectors resulted in a decrease of EGFP-positive cells from 100% (SLRSPPS alone) to 58.2 ± 3.8% (Po0.01) and of RGDLRVS from 100% (RGDLRVS alone) to 56.7 ± 5.0% (Po0.01). In contrast, the controls using non-fluorescent vectors PSLPSRS and SDLRRGV did not alter the transduction efficiency significantly. Importantly, co-incubations of fluorescent SLRSPPS/RGDLRVS vectors with non-fluorescent RGDLRVS/SLRSPPS vectors lowered the transduction efficiencies to 60.8±2.8 (Po0.01) and 51.7±4.2 (Po0.05), respectively, suggesting the partial use of a common transduction mechanism.
The cell surface receptors responsible for AAV9 transduction still remain to be unraveled. However, for AAV2, a cluster of several basic arginines, R588 among them, represent binding sites for HSPG and mutants lacking one or several of these arginine residues exhibit a reduced infectivity. 27, 28 As both, SLRSPPS and RGDLRVS deliver arginine residue(s) to the otherwise argininenegative AAV9 capsid at this site ( Figure 1a) we asked whether our enriched peptides could have re-targeted AAV9 to the HSPG receptor. We incubated HCAECs and HepG2 cells with wt or mutant AAV9 displaying SLRSPPS or RGDLRVS in the presence or absence of solute heparin. Because HepG2 is expressing HSPG, wtAAV2 control--vector efficiently transduced HepG2 in the absence of heparin (94.8±1.5%, Figure 4b ) but failed to do so in its presence (Po0.001). Furthermore, only low transduction efficiencies (o10%) were posed by wt AAV2 (HCAECs) or AAV9 (HCAECs and HepG2). Heparin did not alter the transduction patterns of SLRSPPS on any cell type but did for RGDLRVS to a small, but significant extent (Po0.05 for HCAECs and Po0.01 for HepG2). In summary, we have shown that peptides SLRSPPS and RGDLRVS partially share a common transduction mechanism and that heparin treatment only affects peptide RGDLRVS but not SLRSPPS.
Peptides SLRSPPS and RGDLRVS significantly evade neutralization by antibodies in vitro AAV vectors capable of escaping neutralization by pre-existing antibodies are of high interest in gene therapy. We therefore analyzed the feasibility of our leading mutants SLRSPPS and RGDLRVS to avoid neutralization by capsid antibodies present in human serum in vitro. Co-incubations of wt or mutant vectors with serial dilutions of pooled intravenous immunoglobulin (IVIG) or ADK9, a capsid-binding AAV9 antibody (JA Kleinschmidt, unpublished data), were performed on HEK293T cells using a MOI of 1.5 Â 10 4 g.c./cell. We considered a vector sample as neutralized when transduction efficiency dropped below 50% of the value obtained by vector incubations without serum or antibody. Control wtAAV2 and AAV2-NDVRAVS vectors, which displayed in the absence of IVIG transduction efficiencies of 498%, were neutralized throughout the entire range of dilutions (Figure 5a) . Similarly, wtAAV9 vectors were neutralized by both, IVIG and ADK9 up to dilutions of 1:1280 (translating into 3.125 pg ADK9 antibody per 1.5 Â 10 8 g.c.). However, mutants SLRSPPS and RGDLRVS revealed improved in vitro antibody evasion over wtAAV9, wtAAV2 or AAV2-NDVRAVS about four and eight times, respectively, (B1:320 and B1:160, Figure 5a ) and were only affected by IVIG (Figures 5a and b) . Furthermore, the result correlates with our previous finding that ADK9 recognizes wtAAV9 vectors but not wtAAV2, mutant AAV2 or mutant AAV9 vectors in the context of a capsid enzyme-linked immunosorbent assay (not shown). Our results substantiate that endothelium-targeted AAV9 vectors displaying SLRSPPS or RGDLRVS improve immune escape from human serum antibodies in vitro over wtAAV9, wtAAV2 and AAV2 displaying peptide NDVRAVS, and therefore are more suitable for targeted peptide display than AAV2-based vectors.
Peptide SLRSPPS strongly enhances transduction of human umbilical vein endothelial cells (HUVECs) in human umbilical veins To reproduce our in vitro results in human tissue in situ, we used postnatal human umbilical cords and infiltrated veins with wt or mutant AAV9 vectors displaying SLRSPPS. To facilitate evaluation of transduction efficiency, we isolated HUVECs from veins incubated with vector and expanded them in vitro for 4 days to obtain a sufficient cell amount. Flow cytometry analysis confirmed the presence of endothelial cells, as 99.8±0.06% cells (n ¼ 3) were CD31 positive. Although HUVECs showed a virtually non-existent transduction by wtAAV9, AAV9 displaying peptide SLRSPPS allowed a transduction efficiency of 80.3 ± 11.9% (Po0.001, Figure 6 ). In summary, in vitro selection of the AAV9 library yields endothelium-targeted peptides that improve transduction efficiency of AAV9 not only in cell culture but also in intact human tissue in situ.
DISCUSSION
Efficiency of endothelial gene transfer using AAV vectors is low. Insertion of peptides identified by phage display 7,9,11--13 or selection of random AAV display peptide libraries 8, 10 significantly increased transduction of endothelial cells with AAV2 vectors. The lower prevalence of neutralizing antibodies 14 and a more efficient gene transfer in animal models 17--20 might render human AAV9 more suitable for endothelium targeting than AAV2.
Elucidation of the AAV2 capsid structure 29 together with identification of membrane-attached HSPG as a primary receptor for AAV2 binding and infection 30 as well as isolation of capsid regions involved in HSPG binding 27, 28 enabled a more precise design of AAV2 capsid mutants with altered tissue tropism and enhanced transduction efficiencies. In contrast, only preliminary X-ray crystallographic data of the AAV9 capsid structure were published recently and structure determination is still under progress. 31 Because insertion of heptapeptides behind arginineresidue 588 (R588), part of several basic amino-acid residues clustered within the threefold spike of the capsid surface involved in HSPG binding, 32 altered AAV2 tropism, we reasoned that peptide sequence alignment of AAV2 and AAV9 capsids would indicate the position of similar infection-relevant regions within the AAV9 capsid. AAV2 and AAV9 share about 83% of their capsid amino-acid sequences 33 and sequence comparison of VP3 subunits comprising the HSPG-binding domain revealed highly conserved regions (R484/R485 and R488/R489, (AAV2/AAV9)) as well as variable regions (R585/S586 and R588/A589), which might contribute to the different tissue tropism of these two serotypes.
Comparison of vectors displaying endothelium-targeted control peptide NDVRAVS behind R588 of AAV2 or A589 of AAV9 confirmed our assumption as both mutants were able to transduce HCAECs with significant higher efficiency than both wt AAV2 and AAV9 (Figure 1b) .
A total of four amino acid modifications were necessary to introduce the SfiI site allowing oligopeptide insertion behind residue A589 and preventing capsid formation without peptide insertion (Figure 1a, red letters) , leaving the residual wtAAV9 capsid sequence unaffected. In contrast, other studies intended to create vectors with stronger capsid modifications either by errorprone PCR amplification or by in vitro recombination of parental cap-genes from several AAV serotypes (DNA-family shuffling). 20,22--26 These attempts shared beside improvement of transduction efficiency another common advantage: removal of antigenic epitopes from surface-exposed capsid domains. Neutralizing antibodies in general bind to capsid epitopes, thus preventing interaction of AAV with cellular surface receptor(s). 34 For AAV2, several epitopes have been mapped within the loops of the threefold spike, the most prominent domain of the capsid. 35 Huttner et al. 36 reported two AAV2 mutants carrying peptide insertions I-534 and I-573 with a reduced affinity for AAV antibodies in the majority of the analyzed serum samples. These two insertions, especially I-573, are located in close proximity to R588, probably pointing to a relationship between capsid domains involved in tropism and domains serving as epitopes. We therefore compared the ability of our AAV9 mutants SLRSPPS and RGDLRVS to wt AAV2 and AAV9 vectors as well as to AAV2-NDVRAVS to escape neutralization by IVIG, a pool of human antisera applicable for in vitro neutralization studies of AAV 20, 32 ( Figure 5a ) and ADK9, a monoclonal antibody raised in mice against wtAAV9 capsids (Figure 5b ). AAV9 mutants RGDLRVS and SLRSPPS improved in vitro escape from IVIG neutralization over either wt or AAV2-NDVRAVS, underlining the suitability of AAV9 rather than AAV2 as a backbone for targeted peptide display. Still, IVIG dilutions below 1:160 completely neutralized transduction of the AAV9 mutants. However, the improved evasion lowers the vector dose required for gene transfer attempts thereby reducing the dose-dependent immune response to vectors in treated subjects. 37 We performed in parallel four selection rounds with MOIs 10, 100 and 1000 and analyzed enriched peptides after round three and four (Figure 2a) . Noticeably, the amount of different peptides isolated from the MOI 10 approach was lower and more specific in comparison with other approaches with higher MOIs, although a comparable number of clones was analyzed. Still, RGDLRVS represented the most prominent peptide. SLRSPPS, which confers the best transduction efficiencies to AAV9 vectors (Figure 2b ) by trend, was also present after round three. Therefore, raising the stringency of the selection process by lowering the MOI (and therefore the complexity) of the library may lead to propagation of 'positive' mutants (that is, mutants truly enhancing transduction efficiency) at the same time depleting 'false-positive' mutants that only bind to the cell surface but are neither internalized nor replicated and represent contaminating carryovers in the pool of positive virus mutants.
In addition, not only the peptide but also the serotype backbone it is embedded in seems to influence the transduction efficiency. Cross-display of clones selected from AAV9 libraries on AAV2 capsids and vice versa showed that efficiency of AAV9-derived peptide sequences is generally lower in the AAV2 context. Also most sequences selected on AAV2 resulted in decreased transduction in the AAV9 context, underlining the need of a selection process in the context of the capsid on which the peptide is considered to be expressed (Figure 3b ). These findings confirm our assumption that peptide sequences selected from an library displayed on one serotype not necessarly work in the context of another serotype. Thus, it cannot be generalized from the perfomance of a peptide sequence from one serotype to another, justifying generation of an AAV9 library. Interestingly, NDVRAVS was detected only once (1/25) during the first of three selection rounds on HCAECs 8 but had a transduction efficiency similar to other more frequently enriched peptides. A similar observation was made with SLRSPPS in this study, which was also under-represented after four selection rounds but outperformed the most abundant peptide RGDLRVS. Obviously, there is no correlation between abundance of peptides and their efficiency and therefore criteria for the choice of peptides for further analyzes should be rather their sequence than their abundance. Another important finding is the reasonable transduction efficiency SLRSPPS conferred to AAV9 at the low MOI of 1.000 g.c./cell posing an improvement over the 10-fold higher MOI we previously applied to enable efficient transduction of HCAECs. 8 Such high efficiency with a low vector dose could also be advantageous for a future clinical use because a lower vector exposure might provoke a reduced immune response 37 that complements the ability of this vector to escape neutralizing antibodies.
Some peptides share certain fragments (RGD, SPPS) and nearly all peptides show biased incorporations of single-amino acids (mostly L, N, R and S). The elevated occurrence of these amino acids in peptides from AAV2 libraries selected on different tissues has been reported several times in literature. 8, 21, 24 Our attention was drawn toward arginine residues present in our most efficient peptides. The binding of AAV2 to HSPG receptors depends mainly on a subset of basic arginines (particularly R585/R588) that are absent in the corresponding region of AAV9. According to our results, wtAAV2 vectors efficiently transduced HSPG-positive HepG2 cells in a heparin-dependent manner (Figure 4b ). Because augmentation of missing arginines can be achieved by displaying enriched heptamers such as SLRSPPS and especially RGDLRVS, we analyzed the effect of heparin on transduction efficiencies. For RGDLRVS, relevant (HCAECs) and notable (HepG2) transduction efficiencies were attained, which were slightly modulated by heparin. Because of the minimal inhibitory effect heparin carries on RGDLRVS here and the improved transduction RGDLRVS exercises at the same time on HSPG-deficient HCAECs, a transduction that has been redirected to HSPG receptors can be excluded. The trimer RGD is known to promote binding to a multitude of receptors from the integrin family (reviewed by Ruoslahti et al. 38 ) and it has been demonstrated that integrins have an essential role as cellular entry receptors for AAV2 39 and AAV9. 40 Perabo et al. 21 showed that the expression of RGD at position 587 enables AAV2 to efficiently infect cells via an integrin subtype and, importantly, those RGD-expressing vectors lacked cellular specificity, which the authors ascribed to the wide-ranged expression profile of integrins on different tissues. Our competition experiments suggest that both peptides are capable of competing each other but not if the competing peptide is displayed in a scrambled manner indicating that (i) the peptides specifically modulate transduction patterns and (ii) partly use a common transduction pathway. Because both vectors cannot be completely inhibited by each others, additional alternative receptors/postentry mechanisms might exist, which also could explain different transduction patterns of cell lines and primary cells (Figure 3a ).
An important finding in this study is the suitability of our library to select peptides in vitro, which also efficiently transduce human (umbilical vein) endothelium ex vivo. According to our in vitro data, at least 24 h of incubation upon vector exposition is necessary to detect EGFP expression. Because endothelial integrity was severely affected after 24 h, we were not able to detect EGFP expression in endothelium in cryo-sections of human umbilical veins after incubation with AAV9-SLRSPPS. To overcome these technical limitations, we established a readout using flowcytometry. By thoroughly rinsing veins before harvesting endothelial cells, carry-over of vector contaminations into the cell culture was prevented (see Materials and Methods).
In summary, we have shown the suitability of our AAV9 random peptide library displayed behind residue A589 for selection of peptides with an improved transduction efficiency of HCAECs in vitro. Selected peptides outperformed transduction efficiency of wtAAV9 and AAV9 displaying the known AAV2-library-derived endothelium-targeted peptide NDVRAVS on HCAECs. A more detailed analysis of two enriched peptides, SLRSPPS and RGDLRVS, indicates the partial use of a common transduction mechanism other than HSPG as well as a reduced immunogenicity.
Furthermore, peptide SLRSPPS showed also a high in situtransduction efficiency of human umbilical vein endothelium, rendering this targeting peptide a candidate for future preclinical and clinical approaches.
MATERIALS AND METHODS

Cell culture
All primary cell types used in this study were provided cryo-preserved by Promocell (Heidelberg, Germany) unless otherwise noted. HCAECs and human coronary artery smooth muscle cells were maintained in a medium supplied by the cell provider (C-22120 and C-22162, respectively). Passaging of all primary cells was carried out using the Detach Kit (Promocell). Cell lines HEK293T, HeLa, 911 and HepG2 were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich, Hamburg, Germany) supplemented with 10% heat-inactivated fetal bovine serum (PAA, Coelbe, Germany) and 2 mM L-glutamine (Gibco, Karlsruhe, Germany). Passaging was performed with 0.05% Trypsin-EDTA (Gibco). All media were supplied with 1 Â Pen/Strep/Fungizone solution (Promocell).
AAV vector production and purification
For production of self-complementary (sc) AAV-CMV-EGFP-vectors, rep/ cap-plasmids lacking inverted terminal repeats (ITRs), plasmid pDGDVPcontaining adenovirus helper functions 41 and ITR-positive plasmid dsAAV-CMV-EGFP containing a CMV-EGFP expression cassette 42 were used. Vectors bearing a non-fluorescent CMV-EGFP expression cassette packaged a scCMV-EGFPDGly67 instead of a scCMV-EGFP genome. scCMVEGFPDGly67 was generated by in vitro-mutagenesis with forward 5 0 -GACC ACCCTGACCTACGTGCAGTGCTTCAGCGCG-3 0 and reverse 5 0 -GCGGCTGAAG CACTGCACGTAGGTCAGGGTGGTC-3 0 primers using the Quick Change II Site-Directed Mutagenesis Kit (Stratagene, Waldbronn, Germany). For generation of AAV2-based vectors, rep/cap-plasmids pDP2rs (wt) 43 or pMT187XX2 plus insert (capsid mutants) 44 was used. AAV9 vectors were produced with rep/cap-plasmids p5E18-VD2/9 (wt) 45 or p5E18-VD-2/9-SfiI1759 plus insert (capsid mutants). A total of 1 Â 10 8 HEK293T cells were transfected with EGFP-, rep/cap-and pDGDVP plasmids at a ratio of 1:1.2:3.5 (200, 240 and 700 mg) or 1:3.5 (200 and 700 mg) in case of EGFP and pDP2rs (AAV2 vectors). For transfection, the protocol of Reed et al. 46 was slightly modified: 0.323 g/l PEI (Polysciences, Heidelberg, Germany) was solved in water and freeze-thawed three times. A 80-ml transfection solution containing 150 mM NaCl, plasmid DNA and 9.12 ml PEI-stock (N:Pratio 20) was prepared, incubated 12 min at room temperature to allow DNA--PEI complex formation and was mixed to the medium. After 48--72 h cells were harvested by Trypsin-EDTA and lysed by four freeze-thaw cycles in cell lysis buffer (50 mM Tris Á Cl pH 8.5, 150 mM NaCl, 5 mM MgCl 2 ). Cell lysates were sonified with a Sonorex TK device (Bandelin, Berlin, Germany) for 1 min at 48 W and treated with 100 U Benzonase (Sigma-Aldrich) per ml of lysate for 30 min at 37 1C. AAV particles were then purified by iodixanol density gradient ultracentrifugation as described. 47 Generation of random libraries on the plasmid level A 975-bp fragment of the wtAAV9-cap open reading frame was synthesized (Geneart, Regensburg, Germany, plasmid pGA4) harboring two incompatible SfiI restriction sites separated by two adenines at nucleotide positions 1759 through 1786 of cap9 (Figure 1a) . The modified 975-bp cap9 fragment (cap9mut) was excised with BsiWI/XcmI from pGA4 and was inserted into p5E18-VD-2/9, resulting in p5E18-VD-2/9-SfiI1759. Plasmid p5E18-VD-2/9-SfiI1759 then was digested with HindIII and EcoRV, releasing a 2774-bp fragment containing the entire cap9mut and a part of rep2. This fragment was cloned into pMT-187-XX2. To enable the HindIII/ EcoRV digestion of pMT-187-XX2, the EcoRV site had to be generated by in vitro mutagenesis with the Quick Change II Site-Directed Mutagenesis Kit using forward 5 0 --CAATTACAGATTACGAGTCAGATATCGTGCCAATGGGGC GAG--3 0 and reverse 5 0 --CTCGCCCCATTGGCACGATATCTGACTCGTAATCTG TAATTG--3 0 primers according to the manufacturer's recommendations. The resulting plasmid was named pMT-187-XX2-rep2/cap9mut. Finally, the entire rep2/cap9mut sequence was excised from pMT-187-XX2-rep2/ cap9mut with XbaI and was ligated into ITR-positive plasmid pSSV9 (ref. 48) resulting into the library plasmid backbone pKV-AAV9Lib/BB. To create the oligonucleotide library, a degenerated single-stranded oligonucleotide 5 0 --CAGTCGGCCAAGCAGGC(NNK) 7 GCCCAGGCGGCTGACGAG--3 0 was synthesized encoding a random seven-residue peptide insert flanked by two incompatible BglI restriction sites (University of Freiburg, Oligonucleotide Synthesis Core Facility). This architecture allowed for directional in-frame cloning into SfiI-digested pKV-AAV9Lib/BB plasmid (or p5E18-VD-2/9-SfiI1759 for production of vector-harboring peptides). Second strand synthesis was carried out with the Sequenase Kit (Amersham, Freiburg, Germany) and second strand primer 5 0 --CTCGTCAGCCGCCTGG--3 0 . The double-stranded insert was purified with the QIAquick Nucleotide Removal Kit (Qiagen, Hilden, Germany). Digestion with SfiI cleaved a 12-bp stuffer fragment within pKV-AAV9Lib/BB and the linearized plasmid backbone was purified with the QIAquick PCR Purification Kit (Qiagen). Backbone and insert were ligated at a 1:30 molar ratio and transformed into electrocompetent DH5a bacteria using the Gene Pulser (Biorad, Mü nchen, Germany). Transformed bacteria were grown over night at 30 1C to an OD 600 of 0.2. The plasmid library termed pKV-AAV9Lib was purified using the Qiagen's Plasmid Maxi Kit. Before purification, an aliquot was taken from the culture and serial dilutions were plated on agar plates containing 100 mg/ml ampicillin. Library plasmid complexity was extrapolated for a total of 10 mg transformed library plasmid by determining the number of colonies.
Generation of AAV transfer shuttle library and the random AAV display peptide library A modified two-step protocol was used to create the AAV9 library. 8 After construction of a plasmid library we produced in the first step chimeric wt and mutant AAV capsids, the transfer shuttle library particles by PEI-transfecting 1 Â 10 8 HEK293T cells with the ITR-positive pKV-AAV9Lib plasmid along with ITR-deficient pRSV-VP3co-expressing a codon-optimized wtAAV2 VP3 capsid protein and pDGDVP at a ratio of 1:1:15 (20, 20 and 300 mg). Cells were harvested 72 h posttransfection and transfer shuttle particles were purified by an iodixanol step gradient resulting in a total volume of 2 ml. After determining replicative (3.2 Â 10 12 g.c.) and infectious titers (5 Â 10 7 IU), the final virus library was generated by incubating 1 Â 10 8 HEK293T with the transfer shuttle library at a MOI of 0.5 replicative particles per cell for 4 h in a medium containing 5% fetal bovine serum. For superinfection, transfer shuttle library-containing medium was removed, cells were washed once with 1 Â phosphate-buffered saline and fresh medium containing wtAd5 used at a MOI of 10 infectious particles (ip) per cell was supplied. Harvesting and titration of virus library (4.7 Â 10 11 g.c./ml) occurred 48 h later upon appearance of 50% cytopathic effect induced by Ad.
In vitro biopanning of AAV library on HCAECs
A total of 1 Â 10 6 HCAECs were infected with AAV9 virus library at MOIs of 10, 100 or 1000 g.c./cell. After an incubation of 4 h, AAV9 library-containing medium was removed, cells were washed with 1 Â phosphate-buffered saline and were supplied with fresh medium containing wtAd5 at a MOI of 20 ip/cell. Once an B50% cytopathic effect occurred after 48--72 h, we harvested and titrated library particles as described. These particles were re-applied in the next selection round using the same MOIs. The protocol was repeated three more times resulting in a total of four consecutive selection rounds, whereas individual clones from the third and fourth selection round from each applied MOI were sequenced to identify enriched peptides.
PCR amplification, sequencing and titrating of AAV particles DNA from AAV particles was purified with the QIAamp MinElute Virus Spin Kit (Qiagen) and subjected to standard PCR reaction with AAV9 cap-specific forward 5 0 -GGAGGATCCGCAGGTACAGGTGTGT-3 0 and reverse primer 5 0 -GCTTGATGAATTCTGGACCTGCTATGGC-3 0 spanning the entire oligonucleotide insertion site. PCR products were cloned into pCR-2.1-TOPO (TOPO TA Cloning Kit, Invitrogen, Darmstadt, Germany). Randomly assigned clones were sequenced using the primer 5 0 -CAAACAAGGAACTGGAAGA G-3 0 . Genomic titers were determined by quantitative real-time PCR (TaqMan, Applied Biosystems, Darmstadt, Germany) using CMV-specific or rep-specific primers and probe for vectors and viruses, respectively, as described previously. 49 Replicative titers of AAV virus particles were determined by dot blot analysis. 50 Detection of AAV genomes was performed with a In vitro neutralization assay with wt AAV and single mutants
In a round-bottom multi-well plate (96 well), 1:2 serial dilutions of 10% pooled IVIG (Gamunex R, Talecrid Biotherapeutics, Frankfurt, Germany) or AAV9 capsid antibody ADK9 (JA Kleinschmidt, unpublished data) were made in a total of 30 ml medium lacking fetal bovine serum. The final concentration of ADK9 antibody in the lowest dilution (1:10) was 0.4 ng. Another 30 ml serum-free medium containing AAV-CMV-EGFP vectors (wtAAV2, wtAAV9, mutant AAV2-NDVRAVS, AAV9-RGDLRVS or AAV9-SLRSPPS) were added to the serial dilutions and incubated 45 min at room temperature. Forty out of 60 ml neutralized vector solution resulting in MOIs of 1.5 Â 10 4 g.c./cell were added to 1 Â 10 4 293T cells seeded the day before in a multi-well plate (96 well) in 100 ml medium. Cells were incubated for further 48 h. For analysis of transduction efficiency cells were processed as described above. Neutralization was assumed when transduction efficiency of samples treated with serum was reduced to 50% of mock-treated cells.
Heparin and capsid competition assays with wtAAV and single mutants A total of 5 Â 10 4 HCAECs or 2.5 Â 10 5 HepG2 cells were seeded the day before and were incubated with wt or selected AAV9-CMV-EGFP vectors displaying peptides RGDLRVS and SLRSPPS in the presence or absence of 420 IU/ml heparin (Neolab, Heidelberg, Germany) at MOI 5 Â 10 3 g.c./cell. Wt AAV2-CMV-EGFP vector was used as a positive control. After 4 h, medium containing vectors and/or heparin was replaced by fresh medium, and cells were incubated for a total of 48 h. The capsid competition assay was performed by co-incubation of vectors-harboring fluorescent EGFP expression cassettes and competing vectors containing non-fluorescent EGFPDGly67. A total of 7.5 Â 10 5 HCAECs were seeded and incubated the next day with AAV9-CMV-EGFP mutants displaying SLRSPPS or RGDLRVS alone (efficiencies were set to 100%) or co-incubated with mutant AAV9-CMV-EGFPDGly67 vectors displaying peptides RGDLRVS and SLRSPPS, as well as mutants displaying the scrambled counterparts SDLRRGV and PSLPSRS. Before use, each CMV-EGFPDGly67 vector was tested on HCAECs at MOI 5 Â /cell. After 4 h co-incubation, vector-containing medium was replaced by fresh medium and was further incubated to a total of 48 h. Transduction efficiencies were evaluated by flow-cytometry as described.
